Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inex/Enzon's Marqibo Not Eligible For Accelerated Approval, Committee Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Treatments described in literature constitute "available therapy" to treat relapsed, aggressive non-Hodgkin's lymphoma, cmte. says. Partial responses seen in the pivotal trial of the liposomal vincristine treatment are not reasonably likely to predict a clinical benefit, cmte. finds.

You may also be interested in...

The Greatest FDA Advisory Committees, Part II: The Birth Of The ‘Pazdur Moment’

With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years. This is Part II in the series.

Talon Marqibo’s Fate May Hang On Adjudication Of Trial Subjects

With Talon offering a single Phase II trial to support its NDA for Marqibo (vincristine sulfate liposomal injection) for relapsed Philadelphia chromosome negative acute lymphoblastic leukemia, everything may hinge on the disagreement between the sponsor and FDA over whether eight patients or 13 out of 65 experienced some type of complete response.

Talon May Soon Have First Marqibo Approval In Its Grasp

Biotech formerly known as Hana Biosciences submits NDA for the nano-encapsulated vincristine for use as salvage in adults with Ph- ALL.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts